Cross-Reactive Antibodies to SARS-CoV-2 and MERS-CoV in Pre-COVID-19 Blood Samples from Sierra Leoneans

被引：24

作者：

Borrega, Rodrigo ^{[1
]}

Nelson, Diana K. S. ^{[2
]}

Koval, Anatoliy P. ^{[1
]}

Bond, Nell G. ^{[3
]}

Heinrich, Megan L. ^{[1
]}

Rowland, Megan M. ^{[1
]}

Lathigra, Raju ^{[1
]}

Bush, Duane J. ^{[2
]}

Aimukanova, Irina ^{[2
]}

Phinney, Whitney N. ^{[2
]}

Koval, Sophia A. ^{[1
]}

Hoffmann, Andrew R. ^{[3
]}

Smither, Allison R. ^{[3
]}

Bell-Kareem, Antoinette R. ^{[3
]}

Melnik, Lilia I. ^{[3
]}

Genemaras, Kaylynn J. ^{[3
,4
]}

Chao, Karissa ^{[3
,4
]}

Snarski, Patricia ^{[5
,6
]}

Melton, Alexandra B. ^{[7
]}

Harrell, Jaikin E. ^{[3
]}

Smira, Ashley A. ^{[8
]}

Elliott, Debra H. ^{[8
]}

Rouelle, Julie A. ^{[8
]}

Sabino-Santos Jr, Gilberto ^{[9
,10
]}

Drouin, Arnaud C. ^{[11
]}

Momoh, Mambu ^{[12
,13
,14
]}

Sandi, John Demby ^{[13
]}

Goba, Augustine ^{[13
]}

Samuels, Robert J. ^{[13
]}

Kanneh, Lansana ^{[13
]}

Gbakie, Michael ^{[13
]}

Branco, Zoe L. ^{[1
]}

Shaffer, Jeffrey G. ^{[15
]}

Schieffelin, John S. ^{[8
,16
]}

Robinson, James E. ^{[8
]}

Fusco, Dahlene N. ^{[11
]}

Sabeti, Pardis C. ^{[17
,18
,19
,20
,21
,22
]}

Andersen, Kristian G. ^{[23
,24
]}

Grant, Donald S. ^{[13
,14
]}

Boisen, Matthew L. ^{[2
]}

Branco, Luis M. ^{[1
]}

Garry, Robert F. ^{[1
,2
,3
]}

机构：

[1] Zalgen Labs LCC, Germantown, MD 20876 USA

[2] Zalgen Labs LCC, Broomfield, CO 80045 USA

[3] Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA

[4] Tulane Univ, Bioinnovat Program, New Orleans, LA 70118 USA

[5] Tulane Univ, Sch Med, John W Deming Dept Med, Inst Heart & Vasc, 1430 Tulane Ave, New Orleans, LA 70112 USA

[6] Tulane Univ, Sch Med, Dept Physiol, New Orleans, LA 70112 USA

[7] Tulane Natl Primate Res Ctr, Dept Microbiol, Covington, LA 70433 USA

[8] Tulane Univ, Sch Med, Dept Pediat, New Orleans, LA 70112 USA

[9] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Trop Med, New Orleans, LA 70112 USA

[10] Univ Sao Paulo, Ctr Virol Res, Ribeirao Preto Med Sch, BR-14049900 Ribeirao Preto, SP, Brazil

[11] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA

[12] Eastern Polytech Inst, Kenema, Sierra Leone

[13] Kenema Govt Hosp, Viral Hemorrhag Fever Program, Kenema, Sierra Leone

[14] Minist Hlth & Sanitat, Freetown, Sierra Leone

[15] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Biostat & Data Sci, New Orleans, LA 70112 USA

[16] Tulane Univ, Sch Med, Dept Internal Med, 1430 Tulane Ave, New Orleans, LA 70112 USA

[17] Broad Inst Massachusetts Inst Technol MIT & Harva, Cambridge, MA 02142 USA

[18] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA

[19] Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA

[20] Harvard Univ, Dept Immunol & Infect Dis, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA

[21] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA

[22] Massachusetts Consortium Pathogen Readiness, Boston, MA 02115 USA

[23] Scripps Res, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA

[24] Scripps Res Translat Inst, La Jolla, CA 92037 USA

来源：

VIRUSES-BASEL | 2021年 / 13卷 / 11期

基金：

美国国家卫生研究院;

关键词：

COVID-19 caseloads and deaths; sub-Saharan Africa; pre-existing immunity to coronaviruses; recombinant antigens; enzyme-linked immunosorbent assays; pseudovirus neutralizing antibodies; severe acute respiratory syndrome coronavirus-2; Middle Eastern respiratory syndrome coronavirus; RESPIRATORY-SYNDROME CORONAVIRUS; DROMEDARY CAMELS; AFRICA; COVID-19; INFECTION; KENYA; OUTBREAK; IMMUNITY; BINDING; DOMAIN;

D O I：

10.3390/v13112325

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Many countries in sub-Saharan Africa have experienced lower COVID-19 caseloads and fewer deaths than countries in other regions worldwide. Under-reporting of cases and a younger population could partly account for these differences, but pre-existing immunity to coronaviruses is another potential factor. Blood samples from Sierra Leonean Lassa fever and Ebola survivors and their contacts collected before the first reported COVID-19 cases were assessed using enzyme-linked immunosorbent assays for the presence of antibodies binding to proteins of coronaviruses that infect humans. Results were compared to COVID-19 subjects and healthy blood donors from the United States. Prior to the pandemic, Sierra Leoneans had more frequent exposures than Americans to coronaviruses with epitopes that cross-react with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), SARS-CoV, and Middle Eastern respiratory syndrome coronavirus (MERS-CoV). The percentage of Sierra Leoneans with antibodies reacting to seasonal coronaviruses was also higher than for American blood donors. Serological responses to coronaviruses by Sierra Leoneans did not differ by age or sex. Approximately a quarter of Sierra Leonian pre-pandemic blood samples had neutralizing antibodies against SARS-CoV-2 pseudovirus, while about a third neutralized MERS-CoV pseudovirus. Prior exposures to coronaviruses that induce cross-protective immunity may contribute to reduced COVID-19 cases and deaths in Sierra Leone.

引用

页数：19

共 50 条

[21] Alterations in the Plasma Proteome Induced by SARS-CoV-2 and MERS-CoV Reveal Biomarkers for Disease Outcomes for COVID-19 Patients
Alaiya, Ayodele
Alshukairi, Abeer
Shinwari, Zakia
AL-Fares, Mariam
Alotaibi, Jawaher
AlOmaim, Waleed
Alsharif, Ibtihaj
Bakheet, Razan
Alharbi, Layla
Allam, Rabab
Asiri, Ayed
Memish, Ziad
Alromaih, Khaldoun
Al-Mozaini, Maha
JOURNAL OF INFLAMMATION RESEARCH, 2021, 14 : 4313 - 4328
[22] Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2
Tai, Wanbo
Zhang, Xiujuan
He, Yuxian
Jiang, Shibo
Du, Lanying
ANTIVIRAL RESEARCH, 2020, 179
[23] The Recombination Potential between SARS-CoV-2 and MERS-CoV from Cross-Species Spill-over Infections
Abdulrahim A. Sajini
Almohanad A. Alkayyal
Fathi A. Mubaraki
Journal of Epidemiology and Global Health, 2021, 11 : 155 - 159
[24] The Recombination Potential between SARS-CoV-2 and MERS-CoV from Cross-Species Spill-over Infections
Sajini, Abdulrahim A.
Alkayyal, Almohanad A.
Mubaraki, Fathi A.
JOURNAL OF EPIDEMIOLOGY AND GLOBAL HEALTH, 2021, 11 (02) : 155 - 159
[25] Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2
Ahn, Terrie S.
Han, Brandon
Krogstad, Paul
Bun, Chantana
Kohn, Lisa A.
Garcia-Lloret, Maria I.
Damoiseaux, Robert
Butte, Manish J.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (03) : 876 - 877
[26] Serologic testing of coronaviruses from MERS-CoV to SARS-CoV-2: Learning from the past and anticipating the future
Al-Tawfiq, Jaffar A.
Memish, Ziad A.
TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2020, 37
[27] Source of the COVID-19 pandemic: ecology and genetics of coronaviruses (Betacoronavirus: Coronaviridae) SARS-CoV, SARS-CoV-2 (subgenus Sarbecovirus), and MERS-CoV (subgenus Merbecovirus)
Lvov, Dmitry K.
Alkhovsky, Sergey, V
VOPROSY VIRUSOLOGII, 2020, 65 (02) : 62 - 70
[28] The impact of cross-reactive immunity on the emergence of SARS-CoV-2 variants
Thompson, Robin N.
Southall, Emma
Daon, Yair
Lovell-Read, Francesca A.
Iwami, Shingo
Thompson, Craig P.
Obolski, Uri
FRONTIERS IN IMMUNOLOGY, 2023, 13
[29] Evidence and implications of pre-existing humoral cross-reactive immunity to SARS-CoV-2
Mveang Nzoghe, Amandine
Essone, Paulin N.
Leboueny, Marielle
Maloupazoa Siawaya, Anicet Christel
Bongho, Eliode Cyrien
Mvoundza Ndjindji, Ofilia
Avome Houechenou, Rotimi Myrabelle
Agnandji, Selidji Todagbe
Djoba Siawaya, Joel Fleury
IMMUNITY INFLAMMATION AND DISEASE, 2021, 9 (01) : 128 - 133
[30] SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review
Carvalho Nascimento Junior, Jose Adao
Santos, Anamaria Mendonca
Quintans-Junior, Lucindo Jose
Bandero Walker, Cristiani Isabel
Borges, Lysandro Pinto
Serafini, Mairim Russo
EXPERT OPINION ON THERAPEUTIC PATENTS, 2020, 30 (08) : 567 - 579

← 1 2 3 4 5 →